9 studies were found.

1.		Recruiting	FDG-PET to Investigate SGN-15 and Docetaxel in Patients with Advanced Non-Small Cell Lung Carcinoma Condition: Non-Small Cell Lung Carcinoma
2.		No longer recruiting	Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer Conditions: stage IV breast cancer; recurrent breast cancer
3.		No longer recruiting	Safety/Efficacy study of immunoconjugate with docetaxel in non-small cell lung carcinoma Condition: Carcinoma, Non-Small-Cell Lung
4.		Terminated	Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined with Gemcitabine in Patients with Ovarian Cancer Condition: Ovarian Neoplasms
5.		No longer recruiting	A Safety/Efficacy Study of SGN-30 (Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies Conditions: Hodgkin Disease; Lymphoma, Large-Cell; Sarcoma, Kaposi; Lymphoma, T-Cell, Cutaneous; Lymphoma, B-Cell
6.		No longer recruiting	SGN-15 And Docetaxel in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer Conditions: recurrent non-small cell lung cancer; stage IV non-small cell lung cancer
7.		No longer recruiting	Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer Condition: Prostatic Neoplasms
8.		Recruiting	Study of SGN-30 (Antibody) in Patients with Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma Conditions: Hodgkin's Disease; Anaplastic Large-Cell Lymphoma
9.		Recruiting	Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma Condition: Multiple Myeloma